



PCT/CB2003/00252

10 DEC 2003



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 07 JUL 2003

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC:

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed *Andrew Gersey*  
Dated 25 JUN 2003

BEST AVAILABLE COPY



The  
Patent  
Office



# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

## 1. Your reference

100691

## 2. Patent application number

(The Patent Office will fill in this part)

0213579.6

13 JUN 2002

## 3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB  
S-151 85 Sodertalje  
Sweden

Patents ADP number (if you know it)

7822 44 8003

If the applicant is a corporate body, give the country/state of its incorporation

Sweden

## 4. Title of the invention

METHODS

## 5. Name of your agent (if you have one)

Allen F Giles

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Limited  
Global Intellectual Property  
Mereside, Alderley Park  
Macclesfield  
Cheshire SK10 4TG

Patents ADP number (if you know it)

6988463003

## 6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

## 7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

## 8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (2))

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

19

Claim(s)

3

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents  
(please specify)

9 (Sequence Listing)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Lynda M. Slack

Date

12 Jun 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Lynda M Slack - 01625-516173

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## METHODS

This invention relates to polymorphisms in the human OATP8 gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the OATP8 gene, and to the use of OATP8 polymorphism in treatment of diseases with OATP8 transportable drugs.

Membrane transporters are important for the absorption of oral medications across the gastrointestinal tract, uptake in to target tissues such as the liver or brain, and excretion into the bile and urine. Changes in the activities of transporters may therefore have a significant effect on the bioavailability of clinically important drugs (Hiroyuki Kusunohara *et al.* Journal of Controlled Release 78 (2202) 43-54).

It has been reported in the literature that polymorphisms in proteins involved in drug transport can alter the function of the protein. For example, the multidrug-resistance (MDR-1) gene contains a polymorphism in exon 26 (C345T) which has been correlated with expression levels and function of MDR-1. Individuals homozygous for this polymorphisms have significantly lower duodenal MDR-1 expression and high digoxin plasma levels, suggesting this polymorphism affects the absorption and tissue concentrations of substrates of MDR-1 (S Hoffmeyer *et al.* Proceedings National Academy Science (2000) 97, 3473-3478).

The human sodium independent organic anion transporting polypeptide (OATP) 8 gene is a member of the OATP supergene family involved in multifunctional transport of organic anions (Rommel G *et al.* Journal of Biological Chemistry 276: 35669-35675 (2001); Ikumi Tamai *et al.* Biochemical and Biophysical Research Communications 273, 251-260 (2000)). There is an alternative nomenclature for this family as SLC21A (solute carriers) and OATP8 relates to SLC21A8. OATP8 has been cloned (Jörg König *et al.* Journal of Biological Chemistry 275: 23161-23168 (2000)), and a cDNA sequence encoding OATP8 has been submitted to the EMBL database under accession number AJ251506.

OATP8 has a 79% identity at the amino acid level with its gene family member human OATPC (SLC21A6) and is found on the same gene cluster on chromosome 12. OATPC has broad tissue specificity and is considered to play a major role in hepatic uptake of organic anions including xenobiotics (Gerd A *et al.* Gastroenterology 2001 120: 525-533). OATPC has been shown to be involved in the transport of drugs including benzylpenicillin and those involved in lipid lowering e.g. statins (Daisuke Nakai *et al.* J Pharmacol Exp Ther 2001 297: 861-

867). Statins have been referred to as a first-line therapy for patients with atherosclerotic vascular diseases (Bonnie Hsiang et al. J. Biol Chem 274, 37161-37168 (1999)). OATPC is localized at the basolateral hepatocyte membrane. OATP8 has also been localised to the basolateral hepatocyte membrane. Due to its sequence homology, it is likely that OATP8 may transport similar substrates as OATPC. Indeed, OATP8 has been shown to transport the same organic anions as OATPC, such as sulfobromophthalein and 17 $\beta$ -glucuronosyl estradiol. OATP8 also appears to specifically transport some cardiac glycosides including digoxin. As OATP8 is a liver-specific transporter, the protein coded for by the OATP8 gene may be useful in many liver-specific drug delivery systems.

A screen for polymorphisms in OATP8 in 48 Japanese individuals has been published (Artoshi Iida *et al.* Journal of Human Genetics (2000) 46:668-683) and identifies 80 polymorphisms in OATP8, of which 4 lie in exons. These are Ser112Ala (Exon 3), Leu424Leu (Exon 9), Ala519Ala (Exon 11) and Gly611Gly (Exon 13). The allele frequencies for the individual SNPs are not reported, just the percentage of types of SNPs found.

DNA polymorphisms are variations in DNA sequence between one individual and another. DNA polymorphisms may lead to variations in amino acid sequence and consequently to altered protein structure and functional activity. Polymorphisms may also affect mRNA synthesis, maturation, transportation and stability. Polymorphisms which do not result in amino acid changes (silent polymorphisms) or which do not alter any known consensus sequences may nevertheless have a biological effect, for example by altering mRNA folding or stability.

Knowledge of polymorphisms may be used to help identify patients most suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenetics").

Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection

process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), Clinical Chemistry, 43, 254; Marshall (1997), Nature Biotechnology, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.* (1998), Nature Biotechnology, 16, 33.

Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design and therapy.

Point mutations in polypeptides will be referred to as follows: natural amino acid  
5 (using 1 or 3 letter nomenclature), position, new amino acid. For (a hypothetical) example "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual mutations separated by commas.

The genomic DNA sequence (AC011604) immediately upstream of the OATP8  
10 protein coding sequence is set out as SEQ ID NO: 15, with the first nucleotide of the OATP8 coding region accorded position 417. The position of the polymorphisms in the genomic DNA sequence are defined with reference to SEQ ID NO: 15 unless stated otherwise or apparent from the context.

A cDNA sequence encoding OATP8 (AJ251506) is set out as SEQ ID NO: 16, with  
15 the first nucleotide of the OATP8 coding region accorded position 45. All positions of polymorphisms in the human OATP8 gene transcribed into mRNA (and thence cDNA) herein refer to the positions in SEQ ID NO: 16 unless stated otherwise or apparent from the context.

All positions herein of polymorphisms in the OATP8 polypeptide are defined with reference to SEQ ID NO: 17 unless stated otherwise or apparent from the context.

20 The present invention is based on the discovery of 10 polymorphisms in the human OATP8 gene. The polymorphisms of the present invention may alter the transport of pharmaceutical agents.

According to one aspect of the present invention there is provided a method for the detection of a polymorphism in OATP8 in a human, which method comprises determining the  
25 sequence of the human at any one of the following positions: positions 743, 811, 2021 and 2380 of SEQ ID NO: 16; positions 233 and 256 of SEQ ID NO: 17.

According to a further aspect of the present invention there is provided a method for the detection of a polymorphism in OATP8 in a human, which method comprises  
(ii) determining the sequence of the human, wherein the human is a Caucasian human, at any  
30 one of the following positions: positions 389, 410 and 389-392 of SEQ ID NO: 15; positions 378, 1877 and 2501-2505 of SEQ ID NO: 16; position 112 of SEQ ID NO: 17.

The term "human" includes both a human having or suspected of having an OATP8 mediated response to a drug and an asymptomatic human who may be tested for predisposition or susceptibility to such a response. At each position the human may be homozygous for an allele or the human may be a heterozygote.

- 5       The term "detection of a polymorphism" refers to determination of the genetic status of an individual at a polymorphic position (in which the individual may be homozygous or heterozygous at each position).

10       The term "OATP8 mediated response" means any disease in which changing the level of an OATP8 mediated response or changing the biological activity of OATP8 would be of therapeutic benefit.

The term "polymorphism" includes nucleotide substitution, nucleotide insertion and nucleotide deletion, which in the case of insertion and deletion includes insertion or deletion of one or more nucleotides at a position of a gene and variable numbers of a repeated DNA sequence.

- 15       In one embodiment of the invention preferably the polymorphism is further defined as:
- polymorphism at position 389 is presence of A and/or T;
  - polymorphism at position 410 is presence of T and/or A;
  - polymorphism at position 389-392 is presence of ATAT and/or TAGA;
  - polymorphism at position 743 is presence of A and/or G;
  - 20 polymorphism at position 811 is presence of G and/or C ;
  - polymorphism at position 2021 is presence of G and/or A ;
  - polymorphism at position 2380 is presence of A and/or T;
  - polymorphism at position 378 is presence of G and/or T;
  - polymorphism at position 1877 is presence of A and/or G;
  - 25 polymorphism at position 2501-2505 is presence of AAAAAA and/or AAAAAA;
  - polymorphism at position 233 is presence of Ile and/or Met;
  - polymorphism at position 256 is presence of Gly and/or Ala; and
  - polymorphism at position 112 is presence of Ser and/or Ala.

30       The polymorphism at position 2501-2505 of SEQ ID NO: 16 is the result of an insertion event defined as insertion of A at position 2501 of SEQ ID NO: 16. Because this insertion occurs in a run of A's, the precise position is not definitive but merely changes (A)<sub>5</sub> to (A)<sub>6</sub> in this run of A's. This results in an overall extra one base and it will be appreciated

by the skilled reader that this will have an effect on the numbering of positions downstream of this. For example, position 2501 of SEQ ID NO: 16 becomes position 2502 after the insertion event. It will also be appreciated by the skilled person that it may not be necessary to sequence the exact 2501-2505 bases or the insertion at this position to distinguish between the  
5 two alleles. For example, position 2506 is either T or A when comparing the sequence of the two alleles and this is within the scope of the invention.

The polymorphism at position 389 of SEQ ID NO: 15 is the result of a deletion event defined as deletion of bases 389-406 of SEQ ID NO: 15. This results in 18 bases less overall and it will be appreciated by the skilled person that this will have an effect on the numbering  
10 of the positions downstream of this. For example, position 407 of SEQ ID NO: 15 becomes position 389 after the deletion event. It will also be appreciated by the skilled person that it may not be necessary to sequence the entire 389-406 bases or the deletion at this position to distinguish between the two alleles. For example, position 389 is either an A or a T when comparing the sequence of the two alleles.

15 The polymorphism at position 410 of SEQ ID NO: 15 is the result of a deletion event defined as deletion of bases 410-413 of SEQ ID NO: 15. This results in 4 bases less overall and it will be appreciated by the skilled person that this will have an effect on the numbering of the positions downstream of this. For example, position 414 of SEQ ID NO: 15 becomes position 410 after the deletion event. It will also be appreciated by the skilled person that it  
20 may not be necessary to sequence the entire 410-413 bases or the deletion at this position to distinguish between the two alleles. For example, position 410 is either a T or an A when comparing the sequence of the two alleles.

The polymorphism at position 389-392 of SEQ ID NO: 15 is the result of a double deletion event defined as deletion of bases 389-406 and 410-413 of SEQ ID NO: 15. This  
25 results in 22 bases less overall and it will be appreciated by the skilled person that this will have an effect on the numbering of the positions downstream of this. For example, position 414 of SEQ ID NO: 15 becomes position 392 after the double deletion event. It will also be appreciated by the skilled person that it may not be necessary to sequence the entire 389-406 and 410-413 bases or the deletion at these positions to distinguish between the two alleles.  
30 For example, positions 389-392 are either ATAT or TAGA when comparing the sequence of the two alleles.



Preferred methods for detection of nucleic acid polymorphism are amplification refractory mutation system and restriction fragment length polymorphism.

The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.

It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more polymorphic positions of the invention. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the PCR. These may be used in combination with a number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2<sup>nd</sup> Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

**Abbreviations:**

ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMST™	Amplification refractory mutation system
b-DNA	Branched DNA
bp	base pair
CMC	Chemical mismatch cleavage
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
FRET	Fluorescence resonance energy transfer
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay
NASBA	Nucleic acid sequence based amplification
OATP	Na <sup>+</sup> -independent organic anion transporting polypeptide
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis
UTR	Untranslated region

Table 1 - Mutation Detection Techniques

**General:** DNA sequencing, Sequencing by hybridisation

- 5 **Scanning:** PTT\*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage

\* Note: not useful for detection of promoter polymorphisms.

**Hybridisation Based**

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays

- 10 (DNA Chips)

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst., New York)

- 15 **Extension Based:** ARMST™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.

**Incorporation Based:** Mini-sequencing, APEX

**Restriction Enzyme Based:** RFLP, Restriction site generating PCR

**Ligation Based:** OLA

**Other:** Invader assay

Table 2 - Signal Generation or Detection Systems

- 5 **Fluorescence:** FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom  
Patent No. 2228998 (Zeneca Limited)

**Other:** Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

Table 3 - Further Amplification Methods

- 10 SSR, NASBA, LCR, SDA, b-DNA

Table 4- Protein variation detection methods

Immunoassay

Immunohistology

Peptide sequencing

- 15 Immunoassay techniques are known in the art e.g. A Practical Guide to ELISA by D M Kemeny, Pergamon Press 1991; Principles and Practice of Immunoassay, 2<sup>nd</sup> edition, C P Price & D J Newman, 1997, published by Stockton Press in USA & Canada and by Macmillan Reference in the United Kingdom. Histological techniques are known in the art e.g. Theory and Practice of Histological Techniques, 4<sup>th</sup> Edition, edited by JD Bancroft and A Stevens, Churchill Livingstone, 1996. Protein sequencing is described in Laboratory techniques Biochemistry and Molecular Biology, Volume 9, Sequencing of Proteins and Polypeptides, G Allen, 2<sup>nd</sup> revised edition, Elsevier, 1989.
- 20

Preferred mutation detection techniques include ARMST<sup>TM</sup>, ALEX<sup>TM</sup>, COPS, Taqman, Molecular Beacons, RFLP, restriction site based PCR and FRET techniques, polyacrylamide gel electrophoresis and capillary electrophoresis.

- 25 Particularly preferred methods include ARMST<sup>TM</sup> and RFLP based methods. ARMST<sup>TM</sup> is an especially preferred method.

In a further aspect, the methods of the invention are used to assess the pharmacogenetics of a drug transportable by OATP8.

- 30 Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.

Individuals who carry particular allelic variants of the OATP8 gene may therefore exhibit differences in their ability to regulate protein biosynthesis under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences arising as a result of allelic variation may have a direct effect on the response of an individual to drug therapy. The methods of the invention may be useful both to predict the clinical response to such agents and to determine therapeutic dose.

In a further aspect, the methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by OATP8. The present invention may be used to recognise individuals who are particularly at risk from developing such diseases.

In a further aspect, the methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the OATP8 gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the disease process whilst minimising effects on other variants.

In a further aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes.

According to another aspect of the present invention there is provided a human OATP8 gene or its complementary strand comprising a variant allelic polymorphism at one or more of positions defined herein or a fragment thereof of at least 20 bases comprising at least one novel polymorphism.

Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

According to another aspect of the present invention there is provided a polynucleotide comprising at least 20 contiguous bases of the human OATP8 gene and comprising an allelic variant selected from any of the following:

Region	variant	Position
Exon 6	G	743 (SEQ ID NO: 16)
Exon 7	C	811 (SEQ ID NO: 16)
Exon 14	A	2021 (SEQ ID NO: 16)
3' UTR	T	2380 (SEQ ID NO: 16)

According to a further aspect of the present invention there is provided a polynucleotide comprising at least 20 contiguous bases of the human OATP8 gene, wherein the human is a Caucasian human, and comprising an allelic variant selected from any of the following:

Region	variant	Position
5'UTR	T	389 (SEQ ID NO: 15)
5'UTR	A	410 (SEQ ID NO: 15)
5'UTR	TAGA	389-392 (SEQ ID NO: 15)
Exon 3	T	378 (SEQ ID NO: 16)
Exon 13	G	1877 (SEQ ID NO: 16)
3' UTR	AAAAAA	2501-2505 (SEQ ID NO: 16)

5

According to another aspect of the present invention there is provided a human OATP8 gene or its complementary strand comprising a polymorphism, preferably corresponding with one or more the positions defined herein or a fragment thereof of at least 20 bases comprising at least one polymorphism.

10 Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

The invention further provides a nucleotide primer which can detect a polymorphism of the invention.

According to another aspect of the present invention there is provided an allele  
15 specific primer capable of detecting an OATP8 gene polymorphism, preferably at one or more of the positions as defined herein.

An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as  
20 used for ARMS™ assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4,  
25 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer.

Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1<sup>st</sup> Edition. If  
5 required the primer(s) may be labelled to facilitate detection.

According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting an OATP8 gene polymorphism, preferably at one or more of the positions defined herein.

The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more  
10 preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the  
15 corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection.

According to another aspect of the present invention there is provided an allele  
20 specific primer or an allele specific oligonucleotide probe capable of detecting an OATP8 gene polymorphism at one of the positions defined herein.

According to another aspect of the present invention there is provided a diagnostic kit comprising an allele specific oligonucleotide probe of the invention and/or an allele-specific primer of the invention.

25 The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase.

In another aspect of the invention, the polymorphisms of this invention may be used as genetic markers in linkage studies. This particularly applies to the polymorphisms of  
30 relatively high frequency. The OATP8 gene is on chromosome 12. Low frequency polymorphisms may be particularly useful for haplotyping as described below. A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal

or maternal) chromosome. If recombination within the gene is random, there may be as many as  $2^n$  haplotypes, where 2 is the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes that can be identified in the population of interest. The frequency of each haplotype is limited by the frequency of its rarest allele, so that polymorphisms with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be of low frequency within the population, low frequency polymorphisms may be particularly useful in identifying these mutations (for examples see: De Stefano V *et al. Ann Hum Genet* (1998) 62:481-90; and Keightley AM *et al. Blood* (1999) 93:4277-83).

According to another aspect of the present invention there is provided a computer readable medium comprising at least one novel sequence of the invention stored on the medium. The computer readable medium may be used, for example, in homology searching, mapping, haplotyping, genotyping or pharmacogenetic analysis or any other bioinformatic analysis. The reader is referred to Bioinformatics, A practical guide to the analysis of genes and proteins, Edited by A D Baxevanis & B F F Ouellette, John Wiley & Sons, 1998. Any computer readable medium may be used, for example, compact disk, tape, floppy disk, hard drive or computer chips.

The polynucleotide sequences of the invention, or parts thereof, particularly those relating to and identifying the polymorphisms identified herein represent a valuable information source, for example, to characterise individuals in terms of haplotype and other sub-groupings, such as investigation of susceptibility to treatment with particular drugs. These approaches are most easily facilitated by storing the sequence information in a computer readable medium and then using the information in standard bioinformatics programs or to search sequence databases using state of the art searching tools such as "GCC". Thus, the polynucleotide sequences of the invention are particularly useful as components in databases useful for sequence identity and other search analyses. As used herein, storage of the sequence information in a computer readable medium and use in sequence databases in relation to 'polynucleotide or polynucleotide sequence of the invention' covers any detectable chemical or physical characteristic of a polynucleotide of the invention that may be reduced to, converted into or stored in a tangible medium, such as a computer

disk, preferably in a computer readable form. For example, chromatographic scan data or peak data, photographic scan or peak data, mass spectrographic data, sequence gel (or other) data.

The invention provides a computer readable medium having stored thereon one or  
5 more polynucleotide sequences of the invention. For example, a computer readable medium is provided comprising and having stored thereon a member selected from the group consisting of: a polynucleotide comprising the sequence of a polynucleotide of the invention, a polynucleotide consisting of a polynucleotide of the invention, a polynucleotide which comprises part of a polynucleotide of the invention, which part includes at least one of the  
10 polymorphisms of the invention, a set of polynucleotide sequences wherein the set includes at least one polynucleotide sequence of the invention, a data set comprising or consisting of a polynucleotide sequence of the invention or a part thereof comprising at least one of the polymorphisms identified herein.

A computer based method is also provided for performing sequence identification,  
15 said method comprising the steps of providing a polynucleotide sequence comprising a polymorphism of the invention in a computer readable medium; and comparing said polymorphism containing polynucleotide sequence to at least one other polynucleotide or polypeptide sequence to identify identity (homology), i.e. screen for the presence of a polymorphism.

20 According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a drug transportable by OATP8 in which the method comprises:

- i) detection of a polymorphism in OATP8 in a human, which method comprises determining the sequence of the human at one of the following positions: positions 743, 811,  
25 2021, 2380 of SEQ ID NO: 16; positions 233 and 256 of SEQ ID NO: 17; and
- ii) administering an effective amount of the drug.

In a further aspect of the present invention there is provided a method of treating a Caucasian human in need of treatment with a drug transportable by OATP8 in which the method comprises:

- 30 i) detection of a polymorphism in OATP8 in a human, which method comprises determining the sequence of the human, wherein the human is a Caucasian human, at one of



the following positions: positions 389, 410 and 389-392 of SEQ ID NO: 15; positions 378, 1877 and 2501-2505 of SEQ ID NO: 16; position 112 of SEQ ID NO: 17; and

ii) administering an effective amount of the drug.

Preferably determination of the status of the human is clinically useful. Examples of  
5 clinical usefulness include deciding which statin drug or drugs to administer and/or in  
deciding on the effective amount of the statin drug or drugs. Statins already approved for use  
in humans include atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin. Statins  
under development include rosuvastatin. The reader is referred to the following references for  
further information: Drugs and Therapy Perspectives (12<sup>th</sup> May 1997), 9: 1-6; Chong (1997)  
10 Pharmacotherapy 17: 1157-1177; Kellick (1997) Formulary 32: 352; Kathawala (1991)  
Medicinal Research Reviews, 11: 121-146; Jahng (1995) Drugs of the Future 20: 387-404,  
and Current Opinion in Lipidology, (1997), 8, 362 – 368; Olsson AG, Pears J, McKellar J,  
Mizan J & Raza A (2001) American Journal of Cardiology 88(5): 504-8. The term “drug  
transportable by OATP8” means that transport by OATP8 in humans is an important part of a  
15 drug exerting its pharmaceutical effect in man. For example, some statins have to be  
transported to the liver by OATPC, which is highly homologous to OATP8, to exert their lipid  
lowering effects. Accordingly, OATP8 is expected to be involved in statin transport.

According to another aspect of the present invention there is provided use of a drug  
transportable by OATP8 in preparation of a medicament for treating a disease in a human  
20 determined as having a polymorphism defined herein.

According to another aspect of the present invention there is provided a  
pharmaceutical pack comprising OATP8 transportable drug and instructions for  
administration of the drug to humans tested for a polymorphism described therein, preferably  
at one or more of the positions defined herein.

25 Three of the polymorphisms of the present invention result in variation in the amino  
acid sequence of the translated protein. Polymorphism at position 743 as defined in SEQ ID  
NO: 16 results in an amino acid change from isoleucine to methionine at corresponding  
position 233 of the translated protein (Ile233Met) as defined in SEQ ID NO: 17.  
Polymorphism at position 811 as defined in SEQ ID NO: 16 results in an amino acid change  
30 from glycine to alanine at corresponding position 256 of the translated protein (Gly256Ala) as  
defined in SEQ ID NO: 17. Polymorphism at position 378 as defined in SEQ ID NO: 16

results in an amino acid change from serine to alanine at corresponding position 112 of the translated protein (Ser112Ala) as defined in SEQ ID NO: 17.

Thus according to another aspect of the present invention there is provided an allelic variant of human OATP8 polypeptide comprising:

- 5 a methionine at position 233 of SEQ ID NO: 17;  
an alanine at position 256 of SEQ ID NO: 17;  
an alanine at position 112 of SEQ ID NO: 17;  
or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 233, 256 or 112 of SEQ ID NO: 17.
- 10 Fragments of OATP8 polypeptide are at least 10 amino acids, more preferably at least 15 amino acids, more preferably at least 20 amino acids. The polypeptides of the invention do not encompass naturally occurring polypeptides as they occur in nature, for example, the polypeptide is at least partially purified from at least one component with which it occurs naturally. Preferably the polypeptide is at least 30% pure, more preferably at least 60% pure,  
15 more preferably at least 90% pure, more preferably at least 95% pure, and more preferably at least 99% pure.

According to another aspect of the present invention there is provided an antibody specific for an allelic variant of human OATP8 polypeptide as described herein comprising:  
a methionine at position 233 of SEQ ID NO: 17;

- 20 an alanine at position 256 of SEQ ID NO: 17;  
an alanine at position 112 of SEQ ID NO: 17;  
or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 233, 256 or 112 of SEQ ID NO: 17.

- Antibodies can be prepared using any suitable method. For example, purified  
25 polypeptide may be utilized to prepare specific antibodies. The term "antibodies" is meant to include polyclonal antibodies, monoclonal antibodies, and the various types of antibody constructs such as for example  $F(ab')_2$ , Fab and single chain Fv. Antibodies are defined to be specifically binding if they bind the allelic variant of OATP8 with a  $K_a$  of greater than or equal to about  $10^7 M^{-1}$ . Affinity of binding can be determined using conventional techniques,  
30 for example those described by Scatchard et al., *Ann. N.Y. Acad. Sci.*, 51:660 (1949).

Polyclonal antibodies can be readily generated from a variety of sources, for example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice or rats, using procedures that are

well-known in the art. In general, antigen is administered to the host animal typically through parenteral injection. The immunogenicity of antigen may be enhanced through the use of an adjuvant, for example, Freund's complete or incomplete adjuvant. Following booster immunizations, small samples of serum are collected and tested for reactivity to antigen.

- 5 Examples of various assays useful for such determination include those described in: *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; as well as procedures such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radioimmunoprecipitation, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, and sandwich assays, see U.S. Patent Nos. 4,376,110 and 4,486,530.

- 10 Monoclonal antibodies may be readily prepared using well-known procedures, see for example, the procedures described in U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439 and 4,411,993; *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), (1980).

- The monoclonal antibodies of the invention can be produced using alternative  
15 techniques, such as those described by Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas", *Strategies in Molecular Biology* 3: 1-9 (1990) which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes a specific binding antibody. Such a technique is described in Larrick et al., *Biotechnology*, 7:  
20 394 (1989).

Once isolated and purified, the antibodies may be used to detect the presence of antigen in a sample using established assay protocols, see for example "A Practical Guide to ELISA" by D. M. Kemeny, Pergamon Press, Oxford, England.

- According to another aspect of the invention there is provided a diagnostic kit  
25 comprising an antibody of the invention.

The invention will now be illustrated but not limited by reference to the following examples. All temperatures are in degrees Celsius.

In the examples below, unless otherwise stated, the following methodology and materials have been applied.

- 30 AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable DNA polymerase.

General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989) or in "Current Protocols in Molecular Biology Volumes 1-3", edited by F M Ausubel, R Brent and R E Kingston; published by John Wiley, 1998.

Electropherograms were obtained in a standard manner: data was collected by ABI377 data collection software and the wave form generated by ABI Prism sequencing analysis (2.1.2).

### EXAMPLES

#### 10 Example 1

#### **Identification of Polymorphisms**

##### **1. Methods**

The cDNA sequence of OATP8 (AJ251506) was used to identify the genomic position of the gene and obtain genomic DNA sequence. The genomic DNA sequence was used to design PCR primers to amplify over the exons and intron/exon boundaries of the full length of the OATP gene and some regions upstream of exon 1 and downstream of the final exon. Twenty-nine individual Caucasian genomic DNA samples were used as templates for PCR amplification. The products were then sequenced by dye-primer sequencing. The alignment of sequence traces enabled the identification of polymorphisms. The frequency of the polymorphisms was confirmed by RFLP and primer extension analysis by HPLC (WAVE) method using genomic DNA from 29 individuals and by sequencing. Deletion events were identified by sequencing and allele frequencies determined by amplification across the deletion.

#### **PCR products**

Polymorphism	PCR forward oligo	PCR reverse oligo
Exon 6	(SEQ ID NO: 1)	(SEQ ID NO: 2)
Exon 7	(SEQ ID NO: 3)	(SEQ ID NO: 4)
Exon 14	(SEQ ID NO: 5)	(SEQ ID NO: 6)
3'UTR	(SEQ ID NO: 7)	(SEQ ID NO: 8)

Exon 3	(SEQ ID NO: 9)	(SEQ ID NO: 10)
Exon 13	(SEQ ID NO: 11)	(SEQ ID NO: 12)
3'UTR (position 2501-2505 of SEQ ID NO: 16)	(SEQ ID NO: 7)	(SEQ ID NO: 8)
5'UTR (position 389 of SEQ ID NO: 15)	(SEQ ID NO: 13)	(SEQ ID NO: 14)
5'UTR (position 410 of SEQ ID NO: 15)	(SEQ ID NO: 13)	(SEQ ID NO: 14)
5'UTR (position 389-392 of SEQ ID NO: 15)	(SEQ ID NO: 13)	(SEQ ID NO: 14)

PCR conditions:

1x GeneAmp® PCR buffer II (Roche Molecular Systems Inc.)

100µM of each of dATP, dCTP, dGTP, dTTP

5 1.5mM MgCl<sub>2</sub>

0.5µM of forward and reverse primers

1Unit AmpliTaq Gold® per 25µl PCR reaction (Roche Molecular Systems Inc.)

PCR programme:

10 95°C 10min; (94°C 30sec, 60°C 30sec, 72°C 90 sec) for 35 cycles; 72°C 10 min.

## 2. OATP8 Polymorphisms

15 Sequencing of DNA from 29 individuals identified the following 10 polymorphisms in the OATP8 DNA sequence:

Position	Region	Variation	Resultant codon change	Protein sequence SEQ ID NO 17	Frequency variant allele
389 (SEQ ID NO: 15)	5'UTR	A/T	N/a	N/a	0.24
410 (SEQ ID NO: 15)	5'UTR	T/A	N/a	N/a	0.24
389-392 (SEQ ID NO: 15)	5'UTR	ATAT/TAGA	N/a	N/a	0.24
743 (SEQ ID NO: 16)	Exon 6	A/G	ATA-ATG	Ile233Met	0.08G
811 (SEQ ID NO: 16)	Exon 7	G/C	GGA-GCA	Gly256Ala	0.16C

2021 (SEQ ID NO: 16)	Exon 14	G/A	TCG-TCA	Ser659Ser	0.06A
2380 (SEQ ID NO: 16)	3'UTR	A/T	N/a	N/a	0.92T
378 (SEQ ID NO: 16)	Exon 3	G/T	TCT-GCT	Ser112Ala	0.09T
1877 (SEQ ID NO: 16)	Exon 13	A/G	GGA-GGG	Gly611Gly	0.08G
2501-2505 (SEQ ID NO: 16)	3'UTR	AAAAA/AAAAAA	N/a	N/a	0.25AAAAAA

**Claims**

1. A method for the detection of a polymorphism in OATP8 in a human which method comprises:
  - (i) determining the sequence of the human at any one of the following positions:
    - 5 positions 743, 811, 2021 and 2380 of SEQ ID NO: 16;  
positions 233 and 256 of SEQ ID NO: 17; or
    - (ii) determining the sequence of the human, wherein the human is a Caucasian human, at any one of the following positions:
      - positions 389, 410 and 389-392 of SED ID NO: 15;
      - 10 positions 378, 1877 and 2501-2505 of SEQ ID NO: 16;  
position 112 of SEQ ID NO: 17.
  2. A method according to claim 1 wherein the polymorphism is further defined as:
    - polymorphism at position 389 is presence of A and/or T;
    - polymorphism at position 410 is presence of T and/or A;
    - 15 polymorphism at position 389-392 is presence of ATAT and/or TAGA;
    - polymorphism at position 743 is presence of A and/or G;
    - polymorphism at position 811 is presence of G and/or C ;
    - polymorphism at position 2021 is presence of G and/or A ;
    - polymorphism at position 2380 is presence of A and/or T;
    - 20 polymorphism at position 378 is presence of G and/or T;
    - polymorphism at position 1877 is presence of A and/or G;
    - polymorphism at position 2051-2505 is presence of AAAAA and/or AAAAAA ;
    - polymorphism at position 233 is presence of Ile and/or Met;
    - polymorphism at position 256 is presence of Gly and/or Ala; and
    - 25 polymorphism at position 112 is presence of Ser and/or Ala.
  3. A method according to claim 1 or 2 wherein the method for detection of a nucleic acid polymorphism is selected from amplification refractory mutation system and restriction fragment length polymorphism.
  4. Use of a method defined in any of claims 1-3 to assess the pharmacogenetics of a drug  
30 transportable by OATP8.
  5. A polynucleotide comprising at least 20 contiguous bases of the human OATP8 gene and comprising an allelic variant selected from any of the following:

Region	variant	Position
Exon 6	G	743 (SEQ ID NO: 16)
Exon 7	C	811 (SEQ ID NO: 16)
Exon 14	A	2021 (SEQ ID NO: 16)
3' UTR	T	2380 (SEQ ID NO: 16)

6. An allele specific primer capable of detecting an OATP8 gene polymorphism at one of the following positions: positions 389, 410 and 389-392 of SEQ ID NO: 15; positions 743, 811, 2021, 2380, 378, 1877 and 2501-2505 of SEQ ID NO: 16.
- 5 7. An allele specific oligonucleotide probe capable of detecting a OATP8 gene polymorphism at one of the following positions: positions 389, 410 and 289-392 of SEQ ID NO: 15; positions 743, 811, 2021, 2380, 378, 1877 and 2501-2505 of SEQ ID NO: 16.
8. A diagnostic kit comprising an allele specific oligonucleotide probe of claim 7 and/or an allele-specific primer of claim 6.
- 10 9. A method of treating a human in need of treatment with a drug transportable by OATP8 in which the method comprises detection of a polymorphism in OATP8 in a human, which method comprises:
  - (i) determining the sequence of the human at one of the following positions:
    - positions 743, 811, 2021, 2380 of SEQ ID NO: 16;
    - 15 positions 233 and 256 of SEQ ID NO: 17; or
    - determining the sequence of the human, wherein the human is a Caucasian human, at one of the following positions:
      - positions 389,410 and 389-392 of SEQ ID NO: 15;
      - positions 378, 1877 and 2501-2505 of SEQ ID NO: 16;
      - 20 position 112 of SEQ ID NO: 17; and
    - ii) administering an effective amount of the drug.
  10. Use of a drug transportable by OATP8 in preparation of a medicament for treating a disease in a human determined as having a polymorphism at one of the following positions:
    - positions 389, 410 and 389-392 of SEQ ID NO: 15;
    - 25 positions 743, 811, 2021, 2380, 378, 1877 and 2501-2505 of SEQ ID NO: 16;
    - positions 233, 256 and 112 of SEQ ID NO: 17.
  11. An allelic variant of human OATP8 polypeptide comprising:
    - a methionine at position 233 of SEQ ID NO: 17;
    - an alanine at position 256 of SEQ ID NO: 17;



an alanine at position 112 of SEQ ID NO: 17;

or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 233, 256 or 112 of SEQ ID NO: 17.

12. An antibody specific for an allelic variant of human OATP8 polypeptide as described  
5 herein having:

a methionine at position 233 of SEQ ID NO: 17;

an alanine at position 256 of SEQ ID NO: 17;

an alanine at position 112 of SEQ ID NO: 17;

or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises  
10 the allelic variant at position 233, 256 or 112 of SEQ ID NO: 17.

13. A diagnostic kit comprising an antibody of claim 12.

SEQUENCE LISTING

<110> AstraZeneca AB

5 <120> Methods

<130> JHU/100691-1 GB 10APR02

<140>

10 <141>

<160> 17

<170> PatentIn Ver. 2.1

15

<210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Description of Artificial Sequence:PCR forward  
primer OATP8-1F

25 <400> 1

aggccctgaa tgaatattag agaa

24

<210> 2

30 <211> 25

<212> DNA

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence:PCR reverse  
primer OATPF8-1R

<400> 2

taatgtacgc ttcaatggaa aaat

24

40

<210> 3

<211> 24

<212> DNA

45 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR forward  
primer OATP8-2F  
5  
<400> 3  
ttactttctt catctatgga ggac 24

10 <210> 4  
<211> 24  
<212> DNA  
<213> Artificial Sequence

15 <220>  
<223> Description of Artificial Sequence:PCR reverse  
primer OATP8-2R  
<400> 4  
20 aaagctgact ctagatgatt tgag 24

<210> 5  
<211> 24  
25 <212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR forward  
30 primer OATP8-3F  
<400> 5  
taagatatgc atactgggga gaaa 24

35  
<210> 6  
<211> 23  
<212> DNA  
<213> Artificial Sequence

40  
<220>  
<223> Description of Artificial Sequence:PCR reverse  
primer OATP8-3R

45 <400> 6

100691

- 3 -

ctgcaggatc ttaatgggag gtt

23

&lt;210&gt; 7

5 &lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

10 <223> Description of Artificial Sequence:PCR forward  
primer OATP8-4F

&lt;400&gt; 7

taagatatgc atactgggga gaaa

24

15

&lt;210&gt; 8

&lt;211&gt; 23

&lt;212&gt; DNA

20 &lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:PCR reverse  
primer OATP8-4R

25

&lt;400&gt; 8

ctgcaggatc ttaatgggag gtt

23

30 &lt;210&gt; 9

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

35 &lt;220&gt;

<223> Description of Artificial Sequence:PCR forward  
primer OATP8-5F

&lt;400&gt; 9

40 tttgagggaa ggtacaatgt cttg

24

&lt;210&gt; 10

&lt;211&gt; 24

45 &lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR reverse  
5 primer OATP8-5R

<400> 10

tctcaaaagg taactgccca cttat

24

10

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Description of Artificial Sequence:PCR forward  
primer OATP8-6F

20

<400> 11

tgtaagccaa accaatggaa taat

24

<210> 12

25

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

30

<223> Description of Artificial Sequence:PCR reverse  
primer OATP8-6R

<400> 12

accagaatgc ttgatacaat agtg

24

35

<210> 13

<211> 24

<212> DNA

40

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR forward  
primer OATP8-7F

45

&lt;400&gt; 13

aggccctgaa tgaatattag agaa

24

5 &lt;210&gt; 14

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

10 &lt;220&gt;

<223> Description of Artificial Sequence:PCR reverse  
primer OATP8-7R

&lt;400&gt; 14

15 taatgtacgc ttcaatggaa aaat

24

&lt;210&gt; 15

&lt;211&gt; 500

20 &lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

ttcataaatc ttgtaatctg gatatgtaga aaatataaaa attttaatth ctataattta 60  
25 aaattgttgt tcatacaatc tagtgtgtgg ttttatatta ttacttggt tcaaatttct 120  
ctctatgaaa attatthttc taagcaaatt ataactctct taggctagga gtttgtctct 180  
gtctttctc ctctgtgtcc agcattgacc tagtcctgtg gtcaggaaat agcaggccct 240  
gaatgaatat tagagaatga ttgattgatt gatattgagc ttgtggcttt tcctatthtt 300  
aaattgtata ttgttaaagt aaaataaatt atactthttc thttttaaca ggtgatcatt 360  
30 tcaaaccaag catcagcaac aattaaaaat attcacttgg tatctgtagt ttaataatgg 420  
accaacatca acatthtgaat aaaacagcag agtcagcatc ttcagagaaa aagaaaacaa 480  
gacgctgcaa tggattcaag 500

35 &lt;210&gt; 16

&lt;211&gt; 2646

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

40 &lt;400&gt; 16

atcagcaaca attaaaatat tcacgtggta tctgtagtht aataatggac caacatcaac 60  
atthgaataa aacagcagag tcagcatctt cagagaaaaa gaaaacaaga cgctgcaatg 120  
gattcaagat gttcttggca gccctgtcat tcagctatat tgctaaagca ctaggthgaa 180  
tcattatgaa aatthccatc actcaaatag aaaggagatt tgacatatcc thttctcttg 240  
45 ctggtthaat tgatggaagc thtgaaattg gaaatttgct tgtgattgta thtgtaagth 300

actttggatc taaactacac agaccgaagt taattggaat tggttgtctc cttatgggaa 360  
 ctggaagtat tttgacatct ttaccacatt tcttcatggg atattatagg tattctaaag 420  
 aaacccatat taatccatca gaaaattcaa catcaagttt atcaacctgt ttaattaatc 480  
 aaaccttata attcaatgga acatcacctg agatagtaga aaaagattgt gtaaaggaat 540  
 5 ctgggtcaca catgtggatc tatgtcttca tggggaatat gcttcgtggc ataggggaaa 600  
 ccccatagat accattgggg atttcataca ttgatgattt tgcaaaagaa ggacattctt 660  
 ccttgtattt aggtagtttg aatgcaatag gaatgattgg tccagtcatt ggctttgcac 720  
 tgggatctct gtttgctaaa atgtacgtgg atattggata tgtagatctg agcactatca 780  
 gaataactcc taaggactct cgttgggttg gagcttgggtg gcttgggttc cttgtgtctg 840  
 10 gactattttc cattatcttcc tccataccat ttttttctt gccgaaaaat ccaaataaac 900  
 cacaaaaaga aagaaaaatt tcaactatcat tgcattgtgt gaaaacaaat gatgatagaa 960  
 atcaaacagc taatttgacc aaccaaggaa aaaatgttac caaaaatgtg actgggtttt 1020  
 tccagtcttt gaaaagcatc cttaccaatc ccctgtatgt tatatttctg cttttgacat 1080  
 tgttacaagt aagcagcttt attggttctt ttacttaagt ctttaaataat atggagcaac 1140  
 15 agtacggtca gtctgcatct catgctaact tttgttggg aatcataacc attcctacgg 1200  
 ttgcaactgg aatgttttta ggaggattta tcattaaaaa attcaaattg tctttagttg 1260  
 gaattgccaa attttcatct cttacttcga tgatacctt cttgtttcaa cttctatatt 1320  
 tccctcta atctgcgaaagc aaatcagttg ccggcctaac cttgacctat gatggaaata 1380  
 attcagtggtc atctcatgta gatgtaccac tttcttattg caactcagag tgcaattgtg 1440  
 20 atgaaagtca gtgggaacca gtctgtggga acaatggaat aacttacctg tcaccttgtc 1500  
 tagcaggatg caaatcctca agtgggtatta aaaagcatac agtgttttat aactgtagtt 1560  
 gtgtggaagt aactggtctc cagaacagaa attactcagc acacttgggt gaatgcccaa 1620  
 gagataatac ttgtacaagg aaatttttca tctatgttgc aattcaagtc ataaactctt 1680  
 tgttctctgc aacaggaggt accacattta tcttgttgac tgtgaagatt gttcaacctg 1740  
 25 aattgaaagc acttgcaatg ggtttccagt caatggttat aagaacacta ggaggaattc 1800  
 tagctccaat atattttggg gctctgattg ataaaacatg tatgaagtgg tccaccaaca 1860  
 gctgtggagc acaaggagct tgtaggatat ataattccgt attttttggg aggggtctact 1920  
 tgggcttata tatagcttta agattcccag cacttgtttt atatatgtt ttcatttttg 1980  
 ctatgaagaa aaaatttcaa ggaaaagata ccaaggcatc ggacaatgaa agaaaagtaa 2040  
 30 tggatgaagc aaacttagaa ttcttaaata atgggtgaaca tttgtacct tctgctggaa 2100  
 cagatagtaa aacatgtaat ttggacatgc aagacaatgc tgctgccaac taacattgca 2160  
 ttgattcatt aagatgttat ttttgaggtg ttctgtgtct ttcactgaca attccaacat 2220  
 tctttactta cagtggacca atggataagt ctatgcatct ataataaact ataaaaaatg 2280  
 ggagtaccca tggtaggat atagctatgc ctttatgggt aagattagaa tatatgatcc 2340  
 35 ataaaattta aagtgagagg catgggttagt gtgtgataca ataaaaagta attggttggg 2400  
 agttgtaact gctaataaaa ccagtgacta gaataaagg gaggtaaaaa ggacaagata 2460  
 gattaatagc ctaaataaag agaaaagcct gatgccttta aaaaatgaaa cactttggat 2520  
 gtattactta ggccaaaatc tggcctggat ttatgtata atatatattt tcatgttaag 2580  
 ttgtatattt ttcagaaatt ataaatatta ttaatttaaa attcgaaaaa aaaaaaaaaa 2640  
 40 aaaaaa 2646

&lt;210&gt; 17

&lt;211&gt; 702

45 &lt;212&gt; PRT

<400> 17

**5            1                          5                          10                          15**

10 Ala Leu Ser Phe Ser Tyr Ile Ala Lys Ala Leu Gly Gly Ile Ile Met  
35 40 45

15  
Leu Ala Gly Leu Ile Asp Gly Ser Phe Glu Ile Gly Asn Leu Leu Val  
65 70 75 80

Ile Gly Ile Gly Cys Leu Leu Met Gly Thr Gly Ser Ile Leu Thr Ser  
100 105 110

Ile Asn Pro Ser Glu Asn Ser Thr Ser Ser Leu Ser Thr Cys Leu Ile  
130 135 140

30  
Asn Gln Thr Leu Ser Phe Asn Gly Thr Ser Pro Glu Ile Val Glu Lys  
145 150 155 160

Asp Cys Val Lys Glu Ser Gly Ser His Met Trp Ile Tyr Val Phe Met  
35                   165                   170                   175

Gly Asn Met Leu Arg Gly Ile Gly Glu Thr Pro Ile Val Pro Leu Gly  
180 185 190

40 Ile Ser Tyr Ile Asp Asp Phe Ala Lys Glu Gly His Ser Ser Leu Tyr  
195 200 205

Leu Gly Ser Leu Asn Ala Ile Gly Met Ile Gly Pro Val Ile Gly Phe  
210 . 215 . 220 .

45



Ala Leu Gly Ser Leu Phe Ala Lys Met Tyr Val Asp Ile Gly Tyr Val  
 225 230 235 240  
 Asp Leu Ser Thr Ile Arg Ile Thr Pro Lys Asp Ser Arg Trp Val Gly  
 5 245 250 255  
 Ala Trp Trp Leu Gly Phe Leu Val Ser Gly Leu Phe Ser Ile Ile Ser  
 260 265 270  
 10 Ser Ile Pro Phe Phe Phe Leu Pro Lys Asn Pro Asn Lys Pro Gln Lys  
 275 280 285  
 Glu Arg Lys Ile Ser Leu Ser Leu His Val Leu Lys Thr Asn Asp Asp  
 290 295 300  
 15 Arg Asn Gln Thr Ala Asn Leu Thr Asn Gln Gly Lys Asn Val Thr Lys  
 305 310 315 320  
 Asn Val Thr Gly Phe Phe Gln Ser Leu Lys Ser Ile Leu Thr Asn Pro  
 20 325 330 335  
 Leu Tyr Val Ile Phe Leu Leu Leu Thr Leu Leu Gln Val Ser Ser Phe  
 340 345 350  
 25 Ile Gly Ser Phe Thr Tyr Val Phe Lys Tyr Met Glu Gln Gln Tyr Gly  
 355 360 365  
 Gln Ser Ala Ser His Ala Asn Phe Leu Leu Gly Ile Ile Thr Ile Pro  
 370 375 380  
 30 Thr Val Ala Thr Gly Met Phe Leu Gly Gly Phe Ile Ile Lys Lys Phe  
 385 390 395 400  
 Lys Leu Ser Leu Val Gly Ile Ala Lys Phe Ser Phe Leu Thr Ser Met  
 35 405 410 415  
 Ile Ser Phe Leu Phe Gln Leu Leu Tyr Phe Pro Leu Ile Cys Glu Ser  
 420 425 430  
 40 Lys Ser Val Ala Gly Leu Thr Leu Thr Tyr Asp Gly Asn Asn Ser Val  
 435 440 445  
 Ala Ser His Val Asp Val Pro Leu Ser Tyr Cys Asn Ser Glu Cys Asn  
 450 455 460

Cys Asp Glu Ser Gln Trp Glu Pro Val Cys Gly Asn Asn Gly Ile Thr  
 465 470 475 480  
 Tyr Leu Ser Pro Cys Leu Ala Gly Cys Lys Ser Ser Ser Gly Ile Lys  
 5 485 490 495  
 Lys His Thr Val Phe Tyr Asn Cys Ser Cys Val Glu Val Thr Gly Leu  
 500 505 510  
 10 Gln Asn Arg Asn Tyr Ser Ala His Leu Gly Glu Cys Pro Arg Asp Asn  
 515 520 525  
 Thr Cys Thr Arg Lys Phe Phe Ile Tyr Val Ala Ile Gln Val Ile Asn  
 530 535 540  
 15 Ser Leu Phe Ser Ala Thr Gly Gly Thr Thr Phe Ile Leu Leu Thr Val  
 545 550 555 560  
 Lys Ile Val Gln Pro Glu Leu Lys Ala Leu Ala Met Gly Phe Gln Ser  
 20 565 570 575  
 Met Val Ile Arg Thr Leu Gly Gly Ile Leu Ala Pro Ile Tyr Phe Gly  
 580 585 590  
 25 Ala Leu Ile Asp Lys Thr Cys Met Lys Trp Ser Thr Asn Ser Cys Gly  
 595 600 605  
 Ala Gln Gly Ala Cys Arg Ile Tyr Asn Ser Val Phe Phe Gly Arg Val  
 610 615 620  
 30 Tyr Leu Gly Leu Ser Ile Ala Leu Arg Phe Pro Ala Leu Val Leu Tyr  
 625 630 635 640  
 Ile Val Phe Ile Phe Ala Met Lys Lys Lys Phe Gln Gly Lys Asp Thr  
 35 645 650 655  
 Lys Ala Ser Asp Asn Glu Arg Lys Val Met Asp Glu Ala Asn Leu Glu  
 660 665 670  
 40 Phe Leu Asn Asn Gly Glu His Phe Val Pro Ser Ala Gly Thr Asp Ser  
 675 680 685  
 Lys Thr Cys Asn Leu Asp Met Gln Asp Asn Ala Ala Ala Asn  
 690 695 700

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**